Double Blind Comparative Study of TAK-875
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Fasiglifam (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 28 Feb 2018 Results of an integrated pooled analysis (n=9139) assessing the hepatic safety of fasiglifam from the data of 15 double-blind studies from both global and Japanese development programs (six phase II and nine phase III) including this study, published in the Drug Safety Journal.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2012 New trial record